Trial
NCT03896945
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
—
Condition
Schizophrenia
Intervention
Placebo
Why stopped
Based on the Interim Analysis outcome and recommendation by the DMC, Otsuka approved termination of the study based on futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-24